Kbc Group Nv Ionis Pharmaceuticals Inc Transaction History

Kbc Group Nv

$37 Billion
Q2 2025

A detailed history of Kbc Group Nv transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Kbc Group Nv holds 4,699 shares of IONS stock, worth $345,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,699

Previous 6,515 27.87%

Holding current value

$345,611

Previous $197,000 5.58%

% of portfolio

0.0%

Previous 0.0%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$25.51 - $40.0 $46,326 - $72,640	-1,816 Reduced 27.87%	4,699 $186,000
Q1 2025 Apr 25, 2025	BUY	$30.17 - $34.97 $935 - $1,084	31 Added 0.48%	6,515 $197,000
Q4 2024 Jan 22, 2025	BUY	$33.73 - $40.36 $90,261 - $108,003	2,676 Added 70.27%	6,484 $227,000
Q3 2024 Nov 06, 2024	BUY	$40.06 - $51.86 $16,785 - $21,729	419 Added 12.36%	3,808 $153,000
Q2 2024 Jul 17, 2024	BUY	$36.45 - $47.7 $8,893 - $11,638	244 Added 7.76%	3,389 $162,000
Q1 2024 May 08, 2024	BUY	$42.03 - $53.55 $20,006 - $25,489	476 Added 17.83%	3,145 $136,000
Q4 2023 Feb 13, 2024	BUY	$43.39 - $51.63 $56,016 - $66,654	1,291 Added 93.69%	2,669 $135,000
Q3 2023 Feb 15, 2024	BUY	$38.5 - $47.13 $49,703 - $60,844	1,291 Added 93.69%	2,669 $121,000
Q3 2022 Feb 15, 2024	SELL	$36.54 - $48.66 $47,173 - $62,820	-1,291 Reduced 48.37%	1,378 $61,000
Q2 2022 Feb 14, 2024	SELL	$31.71 - $43.0 $211,220 - $286,423	-6,661 Reduced 82.86%	1,378 $51,000
Q2 2022 Jul 26, 2022	SELL	$31.71 - $43.0 $211,220 - $286,423	-6,661 Reduced 82.86%	1,378 $51,000
Q1 2022 Feb 14, 2024	BUY	$29.88 - $37.04 $657 - $814	22 Added 0.27%	8,039 $298,000
Q1 2022 May 06, 2022	BUY	$29.88 - $37.04 $657 - $814	22 Added 0.27%	8,039 $298,000
Q4 2021 Feb 14, 2024	BUY	$25.61 - $35.1 $136,962 - $187,714	5,348 Added 200.37%	8,017 $244,000
Q4 2021 Feb 03, 2022	SELL	$25.61 - $35.1 $22,920 - $31,414	-895 Reduced 10.04%	8,017 $244,000
Q3 2021 Nov 10, 2021	SELL	$33.54 - $40.55 $97,232 - $117,554	-2,899 Reduced 24.54%	8,912 $299,000
Q2 2021 Aug 11, 2021	BUY	$34.54 - $47.25 $10,362 - $14,175	300 Added 2.61%	11,811 $471,000
Q1 2021 Apr 26, 2021	SELL	$42.51 - $63.78 $8,502 - $12,756	-200 Reduced 1.71%	11,511 $518,000
Q2 2020 Aug 10, 2020	BUY	$46.85 - $61.05 $34,669 - $45,177	740 Added 6.75%	11,711 $691,000
Q1 2020 May 04, 2020	BUY	$41.6 - $63.4 $45,593 - $69,486	1,096 Added 11.1%	10,971 $519,000
Q4 2019 Feb 11, 2020	BUY	$53.85 - $65.27 $15,562 - $18,863	289 Added 3.01%	9,875 $597,000
Q3 2019 Nov 07, 2019	BUY	$59.06 - $72.15 $519,196 - $634,270	8,791 Added 1105.79%	9,586 $574,000
Q2 2019 Dec 03, 2019	BUY	$62.09 - $86.14 $49,361 - $68,481	795 New	795 $51,000
Q2 2019 Jul 30, 2019	SELL	$62.09 - $86.14 $49,361 - $68,481	-795 Closed	0 $0
Q1 2019 Dec 03, 2019	BUY	$52.92 - $81.17 $42,071 - $64,530	795 New	795 $65,000
Q1 2019 May 10, 2019	SELL	$52.92 - $81.17 $42,071 - $64,530	-795 Closed	0 $0
Q4 2018 Dec 03, 2019	BUY	$43.37 - $59.54 $34,479 - $47,334	795 New	795 $43,000
Q4 2018 Jan 31, 2019	SELL	$43.37 - $59.54 $34,479 - $47,334	-795 Closed	0 $0
Q3 2018 Dec 03, 2019	BUY	$42.88 - $53.7 $34,089 - $42,691	795 New	795 $41,000
Q3 2018 Nov 14, 2018	SELL	$42.88 - $53.7 $34,089 - $42,691	-795 Closed	0 $0
Q2 2018 Dec 03, 2019	SELL	$40.53 - $50.7 $43,529 - $54,451	-1,074 Reduced 57.46%	795 $33,000
Q2 2018 Aug 03, 2018	BUY	$40.53 - $50.7 $50,621 - $63,324	1,249 Added 201.45%	1,869 $0
Q1 2018 Dec 03, 2019	SELL	$44.08 - $55.05 $55,055 - $68,757	-1,249 Reduced 66.83%	620 $27,000
Q3 2017 Nov 13, 2017	BUY	$45.56 - $59.57 $85,151 - $111,336	1,869	1,869 $0

Others Institutions Holding IONS

# of Institutions

423

Shares Held

149M

Call Options Held

1.72M

Put Options Held

722K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $10.4B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account